Andere talen Kiora Pharmaceuticals, Inc.

Aandelen

KPRX

US49721T3095

Geschatte realtime Cboe BZX Andere beurzen 21:56:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,519 ^USD	-4,35%		+10,43%	-0,65%

25/03	Kiora Pharmaceuticals, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
09/02	KIORA PHARMACEUTICALS, INC. : HC Wainwright geeft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases, Approval Granted to Initiate Clinical Validation Study	12/04
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study	11/04
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences	05/04
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting	28/03
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases	25/03
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye	08/03
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge	01/02
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million	01/02
Kiora Pharmaceuticals, Inc. announced that it expects to receive $42.274525 million in funding from ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC, Rosalind Advisors, Inc., Stonepine Capital Management LLC, Velan Capital Partners LP	01/02
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties	31/01
Kiora Pharmaceuticals, Inc. Enters into an Exclusive License and Development Agreement with Théa Open Innovation SAS	31/01
Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301	17/11
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa	09/11
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa	04/11
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference	16-10-23
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa	03-10-23
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years	21-09-23
Kiora Pharmaceuticals, Inc. Announces Board Changes	21-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kiora Pharmaceuticals, Inc.

Aandelen

KPRX

US49721T3095

Andere talen

Filters